Ischemic Heart Disease
📧 Sign up to get email alerts when something new happens for Ischemic Heart Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-04-22FDA Approved: CARDIOGEN-82 — Supplemental Application (Bracco Diagnostics Inc)
The FDA approved a supplemental application for CardioGen-82 (Rubidium chloride RB-82) from Bracco Diagnostics Inc. for use in myocardial pe…
-
CLINICAL_TRIALS research · 2013-04-10Clinical Trial Update: Effectiveness New Health Care Organization Model in Primary Care for Chronic Cardiovascular Disease Patients Based [NA]
This clinical trial update describes an evaluation of a new primary care organization model for patients with chronic cardiovascular disease…
-
CLINICAL_TRIALS trial_result · 2013-04-09Clinical Trial Update: FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty [Phase 3]
Phase 3 trial update evaluating whether FFR- or OCT-guided angioplasty improves outcomes for intermediate coronary stenosis in ischemic hear…
-
CLINICAL_TRIALS trial_result · 2013-04-04Clinical Trial Update: Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study) [Phase 2]
A Phase 2 trial (FOCUS Study) examined autologous stem cell therapy for adults with ischemic cardiomyopathy; the study completed and results…
-
FDA label_change · 2013-03-08FDA Approved: MYOVIEW — Supplemental Application (Medi-Physics Inc. dba GE Healthcare)
FDA approved a supplemental application for Myoview (technetium-99m tetrofosmin) to update its labeling after review.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-03-07Clinical Trial Update: Ranolazine for Improving Symptoms of Palpitations [Phase 4]
A Phase 4 clinical trial evaluating ranolazine for improving palpitations in ischemic heart disease. The current status is listed as UNKNOWN…
-
CLINICAL_TRIALS trial_result · 2013-03-05Clinical Trial Update: Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy
This clinical trial update assesses whether ranolazine reduces myocardial ischemia detected by high-field 3T cardiovascular MRI and P-31 spe…
-
FDA approval · 2013-02-25FDA Approved: AMMONIA N-13 — Original Application (Cardinal Health 414, LLC)
FDA approved an original application for Ammonia N-13 (radiopharmaceutical) under an ANDA filed by Cardinal Health 414, LLC.
-
CLINICAL_TRIALS trial_result · 2013-02-21Clinical Trial Update: Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization [NA]
Clinical trial update assessing the safety and effectiveness of Tivoli and Firebird2 drug-eluting stents for coronary revascularization
-
CLINICAL_TRIALS trial_result · 2013-02-20Clinical Trial Update: Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 1: Diagnosis.
This completed clinical trial, CARPA Part 1: Diagnosis, evaluated diagnostic strategies for non-cardiac and undiagnosed chest pain, includin…
-
CLINICAL_TRIALS trial_result · 2013-02-20Clinical Trial Update: Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease [Phase 2]
Report on a Phase 2 clinical trial evaluating extracorporeal shock wave therapy for ischemic heart disease in patients with refractory angin…
-
FDA approval · 2013-02-01FDA Approved: NITROGLYCERIN IN DEXTROSE — Supplemental Application (Baxter Healthcare Company)
FDA approved Baxter's Supplemental Application for Nitroglycerin in Dextrose, adding this intravenous nitroglycerin formulation to the appro…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis [Phase 2, Phase 3]
A completed Phase 2/3 clinical trial comparing cortisone and drug-eluting stents against bare metal stents for restenosis in coronary diseas…
-
CLINICAL_TRIALS trial_result · 2013-01-10Clinical Trial Update: Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)? [Phase 4]
Phase 4 clinical trial update (NCT01295567) evaluates whether dipyridamole can protect against ischemia-reperfusion injury in patients under…
-
CLINICAL_TRIALS research · 2013-01-03Clinical Trial Update: Registry of Cardiovascular Disease Patients
This entry describes a cardiovascular disease patient registry study (NCT01759225) sponsored by Maccabi Healthcare Services in Israel, curre…
-
CLINICAL_TRIALS research · 2012-12-21Clinical Trial Update: To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia
This clinical trial from National Taiwan University Hospital evaluates magnetocardiography as a non-invasive test for ischemic heart disease…
-
FDA approval · 2012-12-14FDA Approved: AMMONIA N 13 — Original Application (SOFIE Co. dba SOFIE)
FDA approved the original application for AMMONIA N 13 from SOFIE, a radiopharmaceutical used in PET imaging to assess myocardial perfusion.
-
CLINICAL_TRIALS trial_result · 2012-12-12Clinical Trial Update: Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) [Phase 4]
Phase 4 trial evaluating whether adding valsartan affects morbidity and mortality in patients with hypertension and ischemic heart disease; …
-
FDA approval · 2012-11-30FDA Approved: EFFIENT — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for EFFIENT (prasugrel hydrochloride) filed by Cosette Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2012-11-30Clinical Trial Update: RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries [NA]
A completed clinical evaluation of the MDT-4107 drug-eluting stent in the treatment of de novo lesions in small diameter native coronary art…
-
FDA approval · 2012-11-26FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Actavis Pharma, Inc.)
FDA approves a supplemental application for verapamil hydrochloride from Actavis Pharma, Inc. for an already authorized product.
-
CLINICAL_TRIALS trial_result · 2012-11-19Clinical Trial Update: Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial [Phase 2]
Phase 2 preliminary trial results evaluate growth hormone therapy in patients with heart failure and growth hormone deficiency. The study, w…
-
CLINICAL_TRIALS trial_result · 2012-10-03Clinical Trial Update: Door-to-door Survey of Cardiovascular Health, Stroke and Ischemic Heart Disease in Atahualpa
A completed door-to-door survey in Atahualpa assessed cardiovascular health with a focus on stroke and ischemic heart disease.
-
CLINICAL_TRIALS trial_result · 2012-09-27Clinical Trial Update: Validation of the Siemens System Somatom Definition and Operating Software for Cardiac CT Studies
This clinical trial update reports on validating the Siemens Somatom Definition CT system and its operating software for cardiac CT studies …
-
CLINICAL_TRIALS research · 2012-09-07Clinical Trial Update: Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler [Phase 2]
Phase II study evaluating the diagnosis and functional assessment of coronary artery disease using transthoracic echodoppler.